BIOR BIOR

Biora Therapeutics Stock Price

4.6025
0.1725 (3.89%)
Upgrade to Real-Time
Regular Market
4.6025
Volume 349,101
Bid Price 4.60
Ask Price 4.62
News -
Day High 4.68

Low
1.95

52 Week Range

High
28.75

Day Low 4.36
Company Name Stock Ticker Symbol Market Type
Biora Therapeutics Inc BIOR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.1725 3.89% 4.6025 13:53:48
Open Price Low Price High Price Close Price Prev Close
4.40 4.36 4.68 4.43
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,592 349,101 $ 4.55 $ 1,589,016 - 1.95 - 28.75
Last Trade Time Type Quantity Stock Price Currency
13:54:42 1 $ 4.61 USD

Period:

Draw Mode:

Biora Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 41.87M 9.10M 6.58M $ 25.61M $ - -67.25 -0.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 24.83M 9.10%

more financials information »

Biora Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BIOR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.264.803.92314.31946,3540.34258.04%
1 Month3.6657.681.955.687,690,4470.937525.58%
3 Months8.258.5251.955.613,555,019-3.65-44.21%
6 Months16.777528.751.9510.352,510,987-12.18-72.57%
1 Year21.5028.751.9512.192,323,834-16.90-78.59%
3 Years21.5028.751.9512.192,323,834-16.90-78.59%
5 Years21.5028.751.9512.192,323,834-16.90-78.59%

Biora Therapeutics Description

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.